在注意力缺陷/多动障碍 (ADHD) 治疗中,阿托莫克西丁和兴奋剂组合的有效性:系统性审查
1Neuroscience and Neurology, Saba University School of Medicine, The Bottom, BES.
Cureus
|March 24, 2025
概括
结合甲基胺与阿托莫克赛丁可以改善治疗耐药病例的ADHD症状严重程度. 然而,坚持的结果是混合的,一些研究显示了改善的坚持,而另一些研究表明停止治疗. 需要进一步的研究.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 精神病学是一个精神病学.
背景情况:
- 注意缺陷/多动障碍 (ADHD) 是一种常见的神经发育障碍.
- 兴奋剂药物,特别是甲基胺,是ADHD的第一线治疗方法.
- 对于对兴奋剂不耐受的患者,考虑非兴奋剂增强策略.
研究的目的:
- 审查最近关于将兴奋剂甲基胺与非兴奋剂阿托莫克赛丁结合用于ADHD的有效性的研究.
- 评估2013年以后发表的研究中的疗效和遵守数据.
主要方法:
- 2012年至2024年间发表的回顾性研究的系统审查.
- 纳入标准侧重于研究甲基化物和阿托莫克赛丁联合治疗ADHD的研究.
- 六项研究符合资格标准.
主要成果:
- 在三项疗效研究中,有两项表明,在组合治疗中治疗耐药的患者中,ADHD的严重程度降低了.
- 在四项坚持性研究中,有三项表明,结合疗法改善了坚持性.
- 一项研究指出,联合治疗有助于停止甲基尼达的治疗.
结论:
- 结合甲基酸盐和阿托莫克赛丁的联合治疗显示出对抗治疗的ADHD的潜力,特别是在疗效方面.
- 坚持的发现是不一致的,需要进一步调查.
- 未来的研究应该集中在特定ADHD亚群的标准化前性研究上.
关键词:
药物治疗的坚持.作为辅助治疗的辅助疗法.亚托莫克西丁 (atomoxetine) 是一种药物.注意缺陷多动障碍 (ADHD) 是一种注意缺陷多动障碍.增强疗法是一种增强疗法.美国CGI-S公司药物治疗的组合药物治疗.甲基化物 (mph) 的含量没有兴奋剂的非兴奋剂更多相关视频
05:48The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
Published on: June 12, 2020
5.6K
13:09Using Brain Activation nir-HEG/Q-EEG and Execution Measures CPTs in a ADHD Assessment Protocol
Published on: April 1, 2018
10.1K
相关概念视频
Attention-Deficit/Hyperactivity Disorder
34
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
34
Antidepressant Drugs: MAOIs and Other Agents
173
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
173
Adrenergic Agonists: Mixed-Action Agents
638
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
638
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
257
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
257
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
147
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
147
Parkinson's Disease: Treatment
166
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
166
